Rchr
J-GLOBAL ID:200901029640667237   Update date: Jan. 31, 2024

Yoshihiro Uto

ウト ヨシヒロ | Yoshihiro Uto
Affiliation and department:
Homepage URL  (1): http://pub2.db.tokushima-u.ac.jp/ERD/person/10780/profile-ja.html
Research field  (1): Bioorganic chemistry
Research theme for competitive and other funds  (26):
  • 2023 - 2026 RCC Precision Medicine Project using PDX models
  • 2021 - 2025 Experimental research on the biological action of nanosecond pulsed electric fields and its evolving to medical technology
  • 2021 - 2024 Design and synthesis of acetylglucose-modified dasatinib and evaluation of radiosensitizing effect
  • 2021 - 2024 多機能性チロシンキナーゼ阻害薬の創出とがん光線力学療法への応用研究
  • 2020 - 2023 消化器癌におけるNa+/H+交換輸送体5の機能解析と特異的阻害薬の開発
Show all
Papers (112):
  • Hirari Yamahana, Yuki Komiya, Takahisa Takino, Yoshio Endo, Hisatsugu Yamada, Chikako Asada, Yoshihiro Uto. Structure-Activity Relationships of UTX-121 Derivatives for the Development of Novel Matrix Metalloproteinase-2/9 Inhibitors. Chemical and Pharmaceutical Bulletin. 2021. 69. 10. 1017-1028
  • Yoshio Endo, Yoshihiro Uto, Yusei Shinohara, Chiaki Abe, Tohru Obata, Yutaka Yonemura, Shun-ichiro Ogura. An iron metabolism-targeting drug with antitumor activity enhances the effect of 5-ALA-based photodynamic therapy. CANCER SCIENCE. 2021. 112. 917-917
  • Yoko Nabeshima, Chiaki Abe, Takeshi Kawauchi, Tomoko Hiroi, Yoshihiro Uto, Yo-ichi Nabeshima. Simple method for large-scale production of macrophage activating factor GcMAF. Scientific Reports. 2020. 10. 1
  • Hirari Yamahana, Takahisa Takino, Yoshio Endo, Hisatsugu Yamada, Takeshi Suzuki, Yoshihiro Uto. A novel celecoxib analog UTX-121 inhibits HT1080 cell invasion by modulating membrane-type 1 matrix metalloproteinase. Biochemical and biophysical research communications. 2020. 521. 1. 137-144
  • Naoki Okamura, Toshiro Ohta, Kazuhiro Kunimasa, Yoshihiro Uto, Shigenori Kumazawa. Antiangiogenic Activity of Flavonols in Chorioallantoic Membrane (CAM) Assay. FOOD SCIENCE AND TECHNOLOGY RESEARCH. 2020. 26. 6. 891-896
more...
MISC (30):
  • 遠藤 良夫, 宇都 義浩, 米村 豊, 小倉 俊一郎, 安部 千秋, 木村 仁. 5-アミノレブリン酸を用いるがんの光線力学的療法の新規効果増強剤TX-816(Enhancing efficacy of ALA-PDT by using the Schiff base derivative TX-816). 日本癌学会総会記事. 2014. 73回. P-3396
  • Integrated cancer therapy combined radiotherapy and immunotherapy : The challenge of using Gc protein-derived macrophage activating factor (GcMAF) as a key molecule. 2013. 48. 2. 199-210
  • 中田 栄司, 森井 孝, 宇都 義浩, 堀 均. 【がん放射線治療の現状と今後に向けて:総説】 がんの特異的な検出を目指した蛍光イメージング法の最近の展開. 放射線生物研究. 2011. 46. 3. 234-246
  • 堀 均, 宇都 義浩, 中田 栄司. Medicinal bricolage design of hypoxia-targeting drugs and invention of boron tracedrugs as next-generation universal drugs. Shikoku acta medica. 2011. 67. 1. 7-14
  • 堀 均, 宇都 義浩, 中田 栄司. 生体の低酸素応答と疾患治療への応用 低酸素標的薬剤のメディシナル・ブリコラージュと次世代医薬品ボロントレースドラッグの創生. 四国医学雑誌. 2011. 67. 1-2. 86-86
more...
Professional career (1):
  • 工学博士(情報)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page